Latest Communications

18 January 2012
APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.

12 July 2011
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners

13 June 2011
APR Applied Pharma Research s.a. and Labtec GmbH announce Ondansetron Oral Dispersible Film (“ODF”) is now available for licensing in Europe and selected non European countries, after having received marketing authorization in most countries of Europe.


oral

ORAL NUTRACEUTICALS

Project Design Planning

APR has experience in the oral nutraceutical formulations development; our approach united to our solid background permit us to give you the best and the most complete support starting from galenic phase to a complete Dossier ready for the Registration7Notification purpose. Before starting with the technical activities are necessary some steps in order to reduce risks of the development

view more



Integrated project development

The steps usually done for a complete development are the following:

view more


Search results